#Gilead Sciences

A look at the supply chain that results in very high costs for HIV and hepatitis C medications.

With funding by the three coordinating centers of the Gilead COMPASS Initiative

Pre-exposure prophylaxis for those who have no health insurance

Located at the Rush Center, the SPOT builds upon the knowledge of people living with HIV.

Why aren’t the very young people whom Truvada as pre-exposure prophylaxis would help the most using this HIV prevention pill?

Three “high-profile advocates” share candid tales as part of Gilead’s video series to prevent HIV and STIs.

The “Healthysexual” campaign features young Black and Latino men, plus cisgender and transgender women. [VIDEO]

Madrigal Pharmaceuticals is the latest company to enter into what’s becoming a crowded market.

These interventions are part of the Southern AIDS Coalition’s COMPASS partnerships.

Venita Ray will manage the group’s role in the $100 million COMPASS initiative.

The Gilead Sciences funding will be carried out in partnership with the Black AIDS Institute.

However, Gilead Sciences, the brand-name manufacturer of Truvada, insists a generic version “will not be immediately available.”

The triple-drug combo would be the first once-daily, single-tablet regimen for those with all genotypes who’ve failed a previous treatment.

Even those who did not qualify for a treatment shorter than 12 weeks did well on the regimen in a real-world study.

Real-world results of eight weeks of the hepatitis C virus treatment Harvoni (ledipasvir/sofosbuvir) are excellent.

Two new treatments have hit the market, offering more options for those with genotypes 3 and 4.